Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Hepatitis Delta International Network (HDIN)

Research output: Contribution to journalReview articlepeer-review

93 Citations (Scopus)

Abstract

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible “trial endpoints”) that could be used across different clinical trials.

Original languageEnglish
Pages (from-to)1008-1015
Number of pages8
JournalJournal of Hepatology
Volume70
Issue number5
DOIs
Publication statusPublished - May 2019

Keywords

  • Hepatitis D
  • New treatment approaches
  • Surrogate marker
  • Treatment endpoints

Fingerprint

Dive into the research topics of 'Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy'. Together they form a unique fingerprint.

Cite this